Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Phase II ECOSPOR study of microbiome therapeutic SER-109 fails to meet primary endpoint

Aug. 1, 2016

University of Cape Town researchers identify new antimalarial candidate

Aug. 1, 2016

University of Illinois discloses antifungal compounds

July 29, 2016

FIOCRUZ patents antituberculosis agents

July 29, 2016

International partnership to tackle the threat posed by antimicrobial resistance

July 29, 2016

DPP Zika IgM/IgG assay obtains CE mark for rapid point-of-care detection of Zika virus

July 28, 2016

Phase I study of FluGen's universal influenza vaccine begins

July 28, 2016

Burnet Institute and ARTES Biotechnology to jointly develop HCV vaccine

July 28, 2016

Pneumococcal vaccination using novel hybrid biological-biomaterial vector

July 28, 2016

NIAID gives grant to Forge Therapeutics to develop drugs for multidrug-resistant bacteria

July 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...